Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: May 6, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Drugs and Targets

Eribulin Receives EU Approval For Unresectable Liposarcoma 

 

The European Commission approved a variation to the terms of the Marketing Authorisation of eribulin for the treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy for advanced or metastatic disease.

The decision is based on the results of Study 309, which was published in The Lancet. The randomized, open-label multicenter phase III study compared the efficacy and safety of eribulin mesilate to dacarbazine in 452 patients aged 18 or over with leiomyosarcomas or liposarcomas.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter